TABLE 3

Treatment Outcome

VariableBevacizumab/IFNα (n = 11)Sunitinib (n = 11)Total population (n = 22)
Response at 3 mo*
 Partial response1 (9)0 (0)1 (5)
 Stable disease8 (73)8 (73)16 (73)
 Progressive disease1 (9)0 (0)1 (5)
 Not evaluable†1 (9)3 (27)4 (18)
Time to progression (wk)
 Median23.730.823.8
 Range11.4–82.4+‡12.9–101+‡11.4–101+‡

  • ↵* According to RECIST1.1.

  • ↵† 4 patients discontinued treatment because of myocardial infarction (n = 2) and hepatotoxicity (n = 1) during sunitinib and bowel perforation at metastatic site (n = 1) during bevacizumab/IFNα.

  • ↵‡ More than.

  • Data are n, with percentages in parentheses.